Table 2.
Association between BP1 mRNA expression and clinicopathological data
| BP1 mRNA | |||
| Factors | Negative | Positive | P |
| Age | 1.00 | ||
| Premenopausal | 2 (17%) | 10 (83%) | |
| (<50 years) | |||
| Postmenopausal | 7 (21%) | 26 (79%) | |
| (≥ 50 years) | |||
| Tumor size | 1.00 | ||
| <2.0 cm | 1 (17%) | 5 (83%) | |
| ≥ 2.0 cm | 7 (19%) | 30 (81%) | |
| Lymph node metastasis | 1.00 | ||
| Negative | 4 (20%) | 16 (80%) | |
| Positive | 4 (18%) | 18 (82%) | |
| Histologic grade | 0.29 | ||
| I | 1 (20%) | 4 (80%) | |
| II | 4 (27%) | 11 (73%) | |
| III | 2 (9%) | 20 (91%) | |
| ER status | 0.03 | ||
| Negative | 0 (0%) | 18 (100%) | |
| Positive | 7 (27%) | 19 (73%) | |
| PR status | 0.02 | ||
| Negative | 1 (4.0%) | 24 (96%) | |
| Positive | 6 (33%) | 12 (67%) | |
| Race | 0.04 | ||
| Caucasian | 6 (43%) | 8 (57%) | |
| African American | 3 (11%) | 25 (89%) | |
ER, estrogen receptor; PR, progesterone receptor. Data were unavailable or indeterminate for parameters as follows: age (one tumor), tumor size (three tumors), lymph node metastasis (four tumors), histologic grade (four tumors), ER status (two tumors), PR status (three tumors), and race (four tumors).